Clinical trials in attention-deficit/hyperactivity disorder (ADHD) have typically measured\noutcome using clinician ratings on the Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth\nEdition (ADHD-RS-IV) and the Clinical Global Impression-Improvement (CGI-I) scale. Remission has\nbeen defined as an endpoint score of less than or equal to 18 on the ADHD-RS-IV (or a mean score\nof 1). Responders have been defined as patients who achieve a CGI-I score of much or very much\nimproved (1 or 2). There is a lack of agreement in the literature on what percent change in symptoms\non the ADHD-RS-IV should be used to define improvement or remission. This study uses data\nfrom a clinical trial of a methylphenidate extended release (MPH-MLR; Aptensio XR®) phase III\nclinical trial to attempt to determine the percent change of symptoms that best corresponds with\nimprovement and remission�����..
Loading....